Renal Denervation

Quantification of Renal Sympathetic Vasomotion as a Novel End Point for Renal Denervation

Peter Ricci Pellegrino, Irving H. Zucker, Yiannis S. Chatzizisis, Han-Jun Wang, Alicia M. Schiller

Abstract—Renal sympathetic denervation, a potentially revolutionary interventional treatment for hypertension, faces an existential problem due to the inability to confirm successful ablation of the targeted renal sympathetic nerves. Based on the observation that renal sympathetic nerve activity exerts rhythmic, baroreflex-driven, and vasoconstrictive control of the renal vasculature, we developed a novel technique for identifying rhythmic sympathetic vascular control using a time-varying, 2-component Windkessel model of the renal circulation. This technology was tested in 2 different animal models of renal denervation; 10 rabbits underwent chronic, surgical renal denervation, and 9 pigs underwent acute, functional renal denervation via intrathecal administration of ropivacaine. Both methods of renal denervation reduced negative admittance gain, negative phase shift renal vascular control at known sympathetic vasomotor frequencies, consistent with a reduction in vasoconstrictive, baroreflex-driven renal sympathetic vasomotion. Classic measures like mean renal blood flow and mean renal vascular resistance were not significantly affected in either model of renal denervation. Renal sympathetic vasomotion monitoring could provide intraprocedural feedback for interventionists performing renal denervation and serve more broadly as a platform technology for the evaluation and treatment of diseases affecting the sympathetic nervous system.

Graphic Abstract—A graphic abstract is available for this article. (Hypertension. 2020;76:1247-1255. DOI: 10.1161/HYPERTENSIONAHA.120.15325.) • Data Supplement

Key Words: baroreflex • heart failure • homeostasis • renal denervation • sympathetic nervous system • vascular resistance

The sympathetic nervous system controls diverse aspects of body homeostasis and plays a maladaptive role in hypertension,1 heart failure,2 and chronic kidney disease.3 Despite the importance of the sympathetic nervous system in health and disease, clinicians lack widely accessible measures of regional sympathetic outflow. The inability to clinically assess this master regulator negatively affects therapies targeting the sympathetic nervous system, acute monitoring of at-risk patients, and patient care for diseases involving the sympathetic nervous system.

Nowhere is this more evident than for renal denervation, a promising antihypertensive intervention that languished for years after a pivotal clinical trial failed to show that renal denervation decreases blood pressure relative to a sham procedure.4 Although many explanations for this efficacy failure were advanced, convincing post hoc analysis of the trial indicated that the patients simply were not denervated,5,6 a fact that was obscured to interventionists by the inability to assess the sympatholytic effect of these devices. With subsequent advances in device design and more sophisticated clinical trial design, renal denervation has been proven effective,7 but a clinically implementable way to validate the removal of the renal sympathetic nerves remains elusive.

Renal sympathetic outflow controls renin release, sodium reabsorption, and renal vascular tone.8 Renal sympathetic vascular control represents an appealing end point for the assessment of sympathetic outflow for numerous reasons, including the availability of existing clinical technologies to measure blood flow in real-time and the potential generalizability of such a technique to other vascular beds. Renal vascular control, however, is particularly complex, with the autoregulatory mechanisms of tubuloglomerular feedback and the myogenic response exerting tight control over renal vascular resistance.9 For this reason, simple static measures like mean renal blood flow (RBF) and renal vascular resistance do not reliably reflect sympathetic tone, and more sensitive, dynamic measures of sympathetic vascular control are needed.

In this study, we identify a baroreflex-driven rhythm in direct renal sympathetic nerve recordings from conscious rabbits, which corresponds to known key sympathetic vasomotor frequencies in rabbits, pigs, and humans. Then, we lay out a novel method for characterizing active rhythmic vascular modulation with clear physiological implications by leveraging the physical relationship between arterial pressure (AP) and RBF. We test this method in both a chronic, surgical renal denervation rabbit model and an acute, functional renal denervation model in swine. We hypothesized that baroreflex-driven
rhythmic renal sympathetic nerve activity (RSNA) would give rise to rhythmic, baroreflex-driven, vasoconstrictive renovascular modulation, termed renal sympathetic vasomotion.

Methods
All methods are further detailed in the Data Supplement.

Data and Materials Availability
The data and source code from this study are available from the corresponding author upon reasonable request.

Rabbit Experiments
Experiments were performed on adult male New Zealand White rabbits. Both rabbit and pig experiments were reviewed and approved by our Institutional Animal Care and Use Committee and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Five rabbits were instrumented with AP telemeters and RSNA electrodes under general anesthesia. After a 1-week recovery period and acclimation to a procedure room, AP and RSNA were recorded. Another 10 rabbits were instrumented with AP telemeters and bilateral RBF probes and underwent unilateral surgical renal denervation under general anesthesia. After a 2-week recovery period and acclimation to a procedure room, AP and bilateral RBF were recorded. At the end of data collection, the nasopharyngeal reflex was elicited to validate unilateral denervation. In a separate experiment, the ganglionic blocker hexamethonium was administered to eliminate global autonomic sympathetic outflow.

Swine Experiments
Experiments were carried out on 9 male domestic swine. Each pig was induced with tiletamine and zolazepam and intubated. Infrathoracic access at the caudal levels of the thoracic spine was obtained after dissection to the interspinous ligament, and an infrathoracic catheter was advanced to the T10/T11 interspace under fluoroscopic guidance. The pig was maintained on a constant infusion of ketamine-midazolam for the remainder of the experiment. Femoral venous and arterial access were obtained, and heparin was administered for thromboprophylaxis. A pressure-flow velocity catheter was advanced to the renal artery; renal AP-flow velocity data were acquired. Functional renal denervation was then performed by administering an infrathoracic bolus of ropivacaine, blocking both afferent and efferent neural transmission around the level of the bolus and resulting in renal sympathetic vasomotion. A pressure-flow velocity catheter was advanced to the renal artery: renal AP-flow velocity data were acquired. Functional renal denervation was then performed by administering an infrathoracic bolus of ropivacaine, blocking both afferent and efferent neural transmission around the level of the bolus and resulting in renal sympathetic vasomotion.

Data Analysis
The relationship between AP and RSNA was analyzed using autospectral and cross-spectral wavelet analysis over a wide physiological frequency range (0.03–2.5 Hz) to identify potentially important sympathetic vasomotor frequencies in rabbits. In brief, AP-RSNA wavelet coherence and AP-RSNA wavelet phase shift were calculated across each 5-minute recording, and group data was visualized by creating occurrence histograms across time using 20 bins of equal size across the ranges [0, 1] and [−π, π] for coherence and phase shift, respectively (illustrated graphically in Figure S1 in the Data Supplement). The novel vasomotion analysis method is introduced alongside Figure 2 and further detailed in the Data Supplement.

Statistical Analysis
Tabular data are displayed as mean±SEM. Statistical testing of simple measures was conducted with 2-tailed, paired *t* tests and, where appropriate, repeated-measures ANOVA with *α* = 0.05. Group occurrence histograms are displayed as mean data for each group with *t* statistics computed for each independent variable pair (eg, frequency-admittance gain bin) to convey directionality, magnitude, and consistency of differences but not statistical significance per se. These *t* statistics were calculated using a 2-tailed, paired *t* test. Due to the high dimensionality of the occurrence data, statistical testing was performed with nonparametric cluster mass-based testing, which allows for a priori significance testing of non-independent, multidimensional data while addressing the inherent multiple comparisons problem. This is illustrated in Figure S2 and detailed further in the Data Supplement.

Results

Rhythmic RSNA
Rabbits were instrumented with RSNA electrodes and AP telemeters to identify sympathetic rhythms likely to give rise to renal sympathetic vasomotion (Figure 1A). Short representative tracings of AP and RSNA show rhythms occurring approximately every 2 seconds in both signals as well as the baroreflex control of RSNA, with low diastolic pressures followed by large bursts of RSNA. Five-minute sections of artifact-free AP and RSNA data underwent wavelet transformation to examine the rhythmic nature of AP and RSNA as well as cross-spectral analysis (Figure 1B). This cross-spectral analysis reveals high coherence between AP and RSNA from 0.2 to 0.75 Hz. The cross-spectral phase shift demonstrates a negative phase shift at this 0.2 to 0.75 Hz frequency range, meaning that oscillations in RSNA follow oscillations in AP, which is consistent with baroreflex-driven control of RSNA. Group data from all 5 rabbits are shown as occurrence histograms in Figure 1C and 1D. The coherence occurrence histogram shows that the AP-RSNA coherence is consistently highest in the 0.2 to 0.75 Hz frequency range, indicating that this is the frequency range with the strongest AP-RSNA relationship (Figure 1C). The phase shift occurrence histogram also shows negative phase shift behavior between 0.2 and 0.75 Hz, indicating baroreflex control of RSNA in this frequency range (Figure 1D). Baseline hemodynamics for these rabbits are shown in Table S1. Taken together, these data demonstrate strong, baroreflex-driven control of RSNA at the 0.2 to 0.75 Hz frequency range in rabbits likely to give rise to renal sympathetic vasomotion.

Novel Method for Vasomotion Assessment
Previous attempts to investigate sympathetic control of the renal vasculature have relied on methods that assumed a rigid renal artery and a time-invariant pressure-flow relationship, failing to account for the reality of pulsatile flow measured in the elastic renal artery that in turn perfuses a circulation whose strong autoregulatory mechanisms dynamically control the relationship between renal AP and flow. We developed a novel method of assessing time-varying, rhythmic modulation of vascular resistance that accounts for the elastic nature of the artery in which flow is measured, and we then applied this method to study renal sympathetic vasomotion.

Pulsatile blood flow measured in an elastic artery can either travel into the capacitive artery or downstream across the arteriolar resistance (Figure 2A), and therefore, arterial blood flow measurements depend on both arterial capacitance and arteriolar resistance. The renal circulation can then be modeled as a 2-element Windkessel with time-varying resistance and capacitance, the electrical circuit abstraction of which is
shown in Figure 2B. As renal sympathetic adrenergic innervation is concentrated most densely on the renal arterioles, this novel method focuses on control of renal vascular resistance. Thus, the resistive component of arterial blood flow was isolated by using the AP waveform to identify short intervals over which the mean arterial blood flow equaled the resistive flow (Figure 2C, see proof in the Data Supplement). Pressure, resistive flow, and resistance enjoy a simple, linear physical relationship. Thus, linear time-varying transfer function analysis of AP and resistive flow reveals modulation of vascular resistance as a function of time and frequency (Figure 2D). This is a powerful lens to view vascular control as the components of the time-varying pressure-resistive flow transfer function each have a clear physiological interpretation. Admittance gain, the transfer function gain normalized by vascular conductance, provides an index of the active buffering of AP oscillations by vascular resistance modulation. Phase shift provides information about timing of oscillations in AP and blood flow, with negative phase shift indicating AP oscillations synchrony, and positive phase shift indicating blood flow oscillations leading resistance modulation. As a corollary, phase shift also implies causality, with negative phase shift consistent with baroreflex control of vascular resistance, zero phase shift consistent with passive Poiseuille flow, and positive phase shift consistent with autoregulatory control of vascular resistance. Coherence quantifies how closely resistive RBF follows AP and is thereby inversely related to the amount of active resistance modulation at a given frequency over a particular time interval.

Thus, this assessment of vasomotion allows for a physiological interpretation of the vascular control of the circulation undergoing pressure-flow monitoring in real-time. Moreover, certain physiological vascular control mechanisms operate primarily at certain frequencies, and thus frequency-guided vasomotion analysis allows one to focus on vascular controllers of interest with greater sensitivity and specificity.

Renal Sympathetic Vasomotion in Surgically Denervated Conscious Rabbits

To assess renal sympathetic vasomotion, rabbits underwent unilateral renal denervation and were instrumented with an AP telemeter and bilateral RBF probes (Figure 3A), allowing for simultaneous assessment of two kidneys exposed to the same systemic milieu and perfusion pressure and differing solely by their sympathetic innervation. The novel vasomotion analysis method outlined above was used to calculate the relationship between AP and RBF of the innervated (INV) and surgically denervated (DNx) kidney at the 0.2 to 0.75 Hz frequency band previously found to contain a strong baroreflex-driven RSNA rhythm in rabbits (Figure 1B). The admittance gain plots for the INV and DNx kidneys of one rabbit show a high prevalence of low admittance gain behavior in the INV kidney that is absent in the DNx kidney, consistent with the elimination of a vasoconstrictive control mechanism by surgical renal denervation. Phase shift for the INV and DNx kidney of this rabbit reveals negative phase shift behavior in the INV kidney which is replaced by zero phase shift behavior in the DNx kidney, consistent with the replacement of a baroreflex-mediated control mechanism by passive laminar flow after surgical renal denervation. Coherence for the INV and
DNx kidneys shows more low-coherence behavior in the INV kidney, consistent with a greater amount of active vascular control in the INV kidney than the DNx kidney at this important sympathetic frequency range.

The results of nonparametric cluster mass-based statistical testing of group data for admittance gain behavior is shown in Figure 3C. As in the representative recording, negative admittance gain behavior is more prevalent in INV kidneys, manifesting as negative $t$ statistics in this region of the difference statistic map in Figure 3C, where DNx kidneys demonstrate more high admittance gain behavior, manifesting as positive $t$ statistics in this region. Significance testing revealed both a statistically significant low admittance gain cluster that was more prevalent in INV kidneys and a statistically significant passive admittance gain cluster that was more prevalent in DNx kidneys. This is consistent with the elimination of an active vasoconstrictive control mechanism and its replacement by passive transduction of AP in this sympathetic frequency range.

Statistical analysis of group data for coherence is shown in Figure 3E. Low-coherence behavior is more common in INV kidneys than DNx kidneys. Statistical testing revealed an expansive, significant cluster of low-coherence behavior that was more common in INV kidneys, and a spatially concentrated, high-coherence cluster more common in DNx kidneys. As coherence is inversely related to active vascular control, this difference is consistent with the elimination of an active vascular control mechanism by renal denervation.

Baseline hemodynamics for these rabbits are shown in Table S2; note that there is no difference in mean RBF between INV and DNx kidneys. Wavelet autospectral parameters did not differ between INV and DNx kidneys (Figure S3). Further vasomotion data can be found in Figure S4. The completeness of surgical renal denervation was functionally confirmed by evoking renal sympathetic vasoconstriction via the nasopharyngeal reflex (Figure S5).

**Effect of Ganglionic Blockade on Sympathetic Vasomotion in Rabbits**

We hypothesized that the observed vasomotion differences between INV and DNx kidneys arose due to the baroreflex-driven, rhythmic RSNA explored in Figure 1, and thus ganglionic blockade with hexamethonium would eliminate these
differences by blocking autonomic outflow. To test this hypothesis, rabbits were administered an intravenous bolus dose of hexamethonium known to eliminate RSNA while AP and bilateral RBF were monitored.

Figure 4A shows representative tracings of AP and bilateral RBF for one rabbit treated with hexamethonium. Figure 4B demonstrates the effect of ganglionic blockade on the 3 components of the time-varying pressure-resistive flow transfer function of each kidney in this representative rabbit. As in Figure 3, the INV kidney exhibits more negative admittance gain behavior than the DNx kidney in the baseline state. This difference is eliminated after administration of hexamethonium, resulting in nearly identical admittance gain plots between the INV and DNx kidneys. Mirroring Figure 3, the INV kidney shows more negative phase shift vasomotion, whereas the DNx kidney shows pressure-flow synchrony. Ganglionic blockade abrogates this difference, resulting in strikingly similar phase shift plots for the INV and DNx kidney after hexamethonium administration. Where the DNx kidney is characterized by passive high-coherence behavior in the baseline state, the INV kidney exhibits low-coherence behavior consistent with active vasomotion. This difference is again eliminated by blocking autonomous ganglionic transmission. Note that movement artifacts are characterized by aberrant vasomotion, independent of innervation or ganglionic blockade.

Group data (n=9) for the hexamethonium experiments are shown in Figure 4C through 4E, with Figure 4C focusing on admittance gain. In the baseline state, INV kidneys exhibit significantly more negative admittance gain behavior, whereas DNx kidneys exhibit more positive admittance gain behavior; the differences between INV and DNx kidneys are eliminated by hexamethonium. Significance testing identified a statistically significant interaction between innervation and ganglionic blockade at this low admittance gain region, indicative that the effect of hexamethonium on admittance gain depends on renal innervation.

Figure 4D shows the group data for phase shift. Before hexamethonium, negative phase shift behavior is significantly more prevalent in INV kidneys, whereas passive, pressure-flow synchrony is significantly more prevalent in DNx kidneys. Again, these differences were eliminated by ganglionic blockade. Significance testing again identified a statistically significant interaction between innervation status and ganglionic blockade at these areas of baseline difference in phase shift between INV and DNx kidneys, indicating that the effect of hexamethonium on phase shift depends on renal innervation.

The coherence group data shows a similar phenomenon (Figure 4E). In the setting of normal ganglionic transmission, low-coherence behavior is significantly more prevalent in INV kidneys and high coherence is more prevalent in DNx kidneys, and this difference is eliminated after administration of hexamethonium. Figure 4E shows a statistically significant interaction between innervation status and hexamethonium.

In summary, administration of hexamethonium eliminates the difference between INV and DNx kidneys, consistent with the hypothesis that the RSNA rhythms observed in Figure 1 drive the observed differences in vasomotion between INV and DNx kidneys.

Group hemodynamics are shown in Figure S6, which demonstrates that hexamethonium significantly reduces AP and raises heart rate but does not significantly affect mean RBF. Additional autospectral and cross-spectral data are shown in Figures S7 through S9; note that wavelet analysis shows that hexamethonium treatment decreases the spectral
energy of the AP and bilateral RBF signals and that hexamethonium greatly impacts the time-varying transfer function of both INV and DNx kidneys.

Renal Sympathetic Vasomotion in Anesthetized Swine Undergoing Acute Functional Denervation

Although the results of these rabbit studies establish a theoretical basis for renal sympathetic vasomotion, this technique needed to be validated with clinical technology in a more translational model. Thus, we tested this novel method in a swine model of acute renal denervation. Anesthetized swine were instrumented with an intrathecal catheter at the T10/T11 level (Movies S1 and S2), and an intravascular pressure-flow velocity wire was advanced to the renal artery (Movie S3). Although recording renal AP and blood flow velocity, functional renal denervation was achieved by injection of an intrathecal bolus of ropivacaine, blocking preganglionic renal sympathetic nerve traffic (Figure 5A).

The vasomotion analysis method was focused on the sympathetic range of 0.03 to 0.10 Hz in swine.\textsuperscript{15} Of note, this frequency range is more analogous to that of man \textendash{} (0.04–0.15 Hz) and presents a clinically relevant challenge as it overlaps with the operating frequencies of renal autoregulatory mechanisms (0.02–0.25 Hz).

Figure 5B shows representative tracings of pulsatile AP and renal AP and blood flow velocity over the course of a single experiment. Time-varying pressure-resistive flow transfer function analysis from this representative pig study is shown in Figure 5C. Admittance gain plots for this experiment reveal a higher prevalence of low admittance gain behavior in the baseline state compared with the postropivacaine state, consistent with the elimination of active vasoconstriction by functional renal denervation. Phase shift plots for this experiment also reveal a reduction in negative phase shift behavior after administration of ropivacaine, indicating a reduction in baroreflex-driven renal vascular modulation. The negative phase shift behavior is replaced by positive phase shift behavior, consistent with active autoregulatory vascular control. Coherence is not obviously affected by ropivacaine administration in this representative experiment, indicating persistent active vasomotion in this frequency range despite renal sympatholysis.

Figure 5D through 5F show occurrence group data for all 9 pigs. As in the representative experiment, low admittance behavior is more prevalent in the baseline state and high admittance behavior is more prevalent after renal sympatholysis (Figure 5D). Again, this is consistent with the abrogation of a vasoconstrictive controller operating at this known sympathetic vasomotor frequency.

Phase shift group data in Figure 5E shows that negative phase shift behavior is significantly more prevalent before administration of intrathecal ropivacaine and, after ropivacaine, positive phase shift behavior is significantly more prevalent. This is indicative of the replacement of baroreflex-driven vascular control by autoregulatory control.

Figure 4. Ganglionic blockade eliminates differences between innervated (INV) and surgically denervated (DNx) kidneys in unilaterally denervated rabbits. A, Tracings of arterial pressure, renal blood flow to the INV kidney, and renal blood flow to the DNx kidney before (Baseline) and after hexamethonium (Hex) administration show the hemodynamic effects of hexamethonium administration in one representative rabbit. B, Representative tracings of admittance gain of the INV kidney before hexamethonium, admittance gain of the DNx kidney after hexamethonium, admittance gain of the DNx kidney before hexamethonium, admittance gain of the DNx kidney after hexamethonium, phase shift of the INV kidney before hexamethonium, phase shift of the INV kidney after hexamethonium, and coherence of the INV kidney after hexamethonium from this rabbit are displayed. C, Statistical testing of admittance gain behavior from all 9 rabbits shows significant INV-DNx differences in the baseline state that are eliminated after hexamethonium treatment and a significant interaction between innervation and ganglionic blockade. D, Statistical testing of phase shift behavior from all rabbits shows significant INV-DNx differences in the baseline state that are eliminated after hexamethonium treatment and a significant interaction between innervation and ganglionic blockade. E, Statistical testing of coherence behavior from all rabbits shows significant INV-DNx differences in the baseline state that are eliminated after hexamethonium treatment and a significant interaction between innervation and ganglionic blockade. NS indicates non-significant interaction.
Figure 5F shows group data for coherence for the swine study. Unlike surgical renal denervation in rabbits, functional renal denervation in swine does not significantly affect coherence, a marker of the amount of active renovascular control. Baseline hemodynamics for swine are shown in Table S3, intrathecal ropivacaine did not significantly affect AP, heart rate, or renal AP and blood flow velocity. Autospectral data are shown in Figure S10; note that AP spectral power in this sympathetic frequency range is reduced after intrathecal ropivacaine administration, consistent with effective sympatholysis. Additional renal vasomotion data are found in Figure S11.

Renal Denervation Decreases Quantifiable Renal Sympathetic Vasomotion

The above multidimensional renal vasomotion data, although identifying a renal sympathetic vascular control signature in both rabbits and swine, are not readily interpretable for intraprocedural decision-making. To address this, renal sympathetic vasomotion was quantified as the cumulative occurrence of vasoconstrictive, baroreflex-mediated renal vasomotion arising at sympathetic vasomotor frequencies. Renal sympathetic vasomotion was significantly decreased in the surgically denervated kidney of all ten rabbits (Figure 6A). Intrathecal ropivacaine also significantly decreased quantifiable renal sympathetic vasomotion in swine (Figure 6B). Thus, this simplistic, a priori quantification method reflects changes in renal sympathetic outflow in 2 distinct preclinical models of renal denervation and could potentially be generalized for intraprocedural clinical use.

Discussion

Although, in general, the results from the rabbit and swine models of renal denervation are largely corroborative, a few key differences merit further discussion. The autoregulatory control mechanisms of the kidney operate between 0.02 and 0.25 Hz in all species in which they have been studied:
conversely, the sympathetic rhythms that give rise to Mayer waves occur at species-specific frequencies. In rabbits, the 0.2 to 0.75 Hz RSNA rhythm that we identified operates in a distinct frequency range with little overlap of that of the autoregulatory mechanisms. Conversely, in pigs and humans, the sympathetic rhythms operate entirely in the frequency range of the autoregulatory controllers. Thus, although renal denervation in both rabbits and swine reduced the amount of negative phase shift behavior, consistent with a reduction in baroreflex control, in rabbits, this behavior was replaced by pressure-flow synchrony, consistent with a passive pressure-flow relationship, whereas in pigs it was replaced by positive phase shift behavior, consistent with active autoregulatory control. Similarly, coherence, which is inversely related to the amount of active vascular control, was increased by renal denervation in rabbits but not pigs. This reflects the fact that active autoregulatory vasomotion continues in pigs at the frequency of interest; whereas in rabbits there is no other vascular control mechanism that operates in this 0.2 to 0.75 Hz frequency range.

The most immediate potential implications of this technology pertain to the field of therapeutic renal denervation where interventionists have no way of validating the success of a procedure. Renal sympathetic vasomotion monitoring could be performed clinically using the same approach employed for swine with real-time assessment of renal sympathetic vasomotion used to provide intraprocedural feedback for clinicians. Measurement of renal AP-flow might be performed to measure baseline renal sympathetic vasomotion and then again after catheter-based renal denervation to verify effective denervation or, if the drop in renal sympathetic vasomotion were unsatisfactory, prompt an additional ablation. Such feedback could improve the efficacy, safety, and usability of this antihypertensive therapy. Moreover, as renal sympathetic vasomotion can be characterized noninvasively (eg, using transabdominal Doppler to measure RBF velocity and a volume-clamp device to measure AP), this technology could also be used to identify potential therapy responders before the procedure and to monitor for reinervation after a successful procedure.

Beyond this, our approach has applications to other processes involving the sympathetic nervous system. As the sympathetic nervous system is the endogenous hemodynamic monitoring system and first-responder, the ability to detect acute subclinical activation of the sympathetic nervous system may improve our ability to identify patients at risk for hemodynamic compromise and to intervene earlier. A more clinically viable method may also help improve the diagnosis, treatment, and understanding of chronic diseases like dysautonomia, chronic heart failure, hypertension, and chronic kidney disease. Similarly, this method provides a powerful lens for assessing active vascular control of any origin. This approach could be used to characterize autoregulatory control on a patient-by-patient basis and to create technologies designed to optimize the perfusion pressure of vital organs.

This method makes 2 assumptions: (1) that perfusion pressure can adequately be approximated by AP and (2) the renal pressure-flow relationship can acceptably be described by a time-varying, 2-component Windkessel lumped model. This is a significant advancement over previous analysis of the renal circulation that assumed a time-invariant (ie, constant) pressure-flow relationship, which is incompatible with the known importance of renal autoregulation, and did not account for the elastic nature of the renal artery. This may explain why previous studies investigating the importance of sympathetic control of the renal vasculature have arrived at such heterogenous conclusions.16–19 That said, all vascular trees are known to exhibit viscoelastic and inductive properties that are absent in our model. The renal circulation specifically is even more complex, boasting a dual series arteriolar network with filtration function.

Our study has several limitations. For example, we are unable to quantify the density of the intrathecal ropivacaine blockade, but we are certain that it is not as complete as the surgical denervation procedure. As early studies in humans indicate that full renal denervation was never achieved with the early endovascular radiofrequency ablation devices,26 this may render the study more clinically relevant. Additionally, we did not simultaneously measure RBF and RSNA in the same kidney, which would have been a very elegant, albeit technically challenging, model to further characterize renal sympathetic vasomotion. Furthermore, this study was performed in healthy animals and leaves unaddressed the added complexity of pathophysiology of human cardiovascular disease and its potential impact on renovascular control.

To be translated to the clinic, similar preclinical studies in which renal denervation is performed with minimally invasive, state-of-the-art clinical devices and compared against a gold-standard surgical denervation would provide important insights while avoiding the circular logic of validating a new diagnostic technology with an unverifiable intervention. Moreover, acquisition of renal AP and flow velocity signals in patients undergoing renal denervation procedures should be designed to further address issues about feasibility and safety in human hypertensive subjects.

**Perspectives**

In this article, we identified a baroreflex-mediated RSNA rhythm that we hypothesized would give rise to rhythmic modulation of the renal vasculature, termed renal sympathetic vasomotion. We developed a novel method for characterizing rhythmic vascular modulation using measurements of simultaneous arterial blood pressure and RBF, and we tested it in 3 different models of renal denervation. First, we tested the technique in conscious rabbits that underwent unilateral surgical renal denervation and instrumentation with bilateral RBF probes. In these rabbits, INV kidneys exhibited more negative admittance, negative phase shift, and low-coherence behavior compared with their DNx counterparts, consistent with the presence of vasoconstrictive, baroreflex-mediated, active vasomotion caused by rhythmic RSNA. Next, ganglionic blockade with hexamethonium was used to acutely eliminate global sympathetic nerve activity, and this also eliminated the differences between INV and DNx kidneys, further corroborating the hypothesis that this vasomotion was the result of rhythmic RSNA. Finally, this novel method was tested in anesthetized pigs that underwent acute functional renal sympathetic denervation with thoracic intrathecal ropivacaine while renal artery pressure and flow velocity were monitored with a clinically approved intravascular catheter.
Again, functional renal denervation reduced the amount of negative admittance gain and negative phase shift behavior, consistent with the abrogation of a vasoconstrictive, baroreflex-mediated renovascular control mechanism. Additionally, quantifying renal sympathetic vasomotion as the amount of vasoconstrictive, baroreflex-mediated renal vasomotion reflected expected differences in renal sympathetic outflow both in surgically denervated rabbits and functionally denervated pigs. In summary, this novel method for assessing vasomotion demonstrates active baroreflex-mediated, vasoconstrictive control of the renal circulation by the sympathetic nervous system (Graphical Abstract).

Acknowledgments
We thank Kaye Talbitzer, John Lof, Elizabeth Stolze, Gretchen Fry, and Tara Rudebush for their technical assistance.

Sources of Funding
Supported by National Institutes of Health (NIH) P01 HL62222, NIH F30 HL118974, and a Nebraska Research Initiative Proof-of-Concept Grant.

Disclosure
P.R. Pellegrino has received honoraria and travel expenses from Medtronic plc. P.R. Pellegrino, I.H. Zucker, Y.S. Chatzizisis, and A.M. Schiller have submitted a relevant provisional patent application (Docket No. 18060P, Serial No. PCT/US17/23557) related to this work.

References

Novelty and Significance
What Is New?
• We developed a novel technique called sympathetic vasomotion, a marker of sympathetic control of the renal vasculature that could be used as a clinical end point for evaluating effective renal denervation.

What Is Relevant?
• Renal denervation is a paradigm-shifting antihypertensive intervention that has struggled to gain traction due to the inability to validate procedural success; sympathetic vasomotion could address this problem.

Summary
We introduced sympathetic vasomotion and demonstrated its validity both in a highly controlled rabbit model and a clinically relevant swine model of renal denervation. This technique could provide intraprocedural feedback for interventionists performing therapeutic renal denervation.